Octagam (Human Normal Immunoglobulin)

The pooled IgG antibodies in Octagam bind to a wide range of antigens, neutralising pathogens and toxins. Interaction with Fc receptors on immune cells modulates complement activation and cytokine release, helping to restore immune balance and reduce autoimmune inflammation.

The dose of Octagam is individualized by the prescribing clinician based on the patient’s condition, body weight, and clinical response. Physicians calculate the appropriate volume and infusion rate for each treatment course.

Human immunoglobulin products, including Octagam, are generally considered low risk during pregnancy and lactation because they are not actively transferred in harmful amounts. However, treatment decisions should be made by a healthcare professional weighing potential benefits and risks.

To order Octagam, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Octagam is an EU‑origin IVIG with a high IgG purity and low IgA content, which may reduce the risk of anti‑IgA reactions compared with some alternatives. Clinical efficacy and safety are comparable to other licensed IVIG preparations, though specific formulation differences can influence tolerability and infusion rates.

Octagam must be stored refrigerated between 2 °C and 8 °C, protected from light, and must never be frozen or shaken. Before use, the solution should be allowed to reach room temperature and inspected for particulates or discoloration.

Octagam is given as an intravenous infusion under medical supervision. The infusion rate is started slowly and may be increased as tolerated, typically over several hours, depending on the dose prescribed and patient response.

Serious adverse events include anaphylaxis, acute hemolytic anemia, thromboembolic complications, renal failure, severe aseptic meningitis, and transfusion‑related acute lung injury (TRALI). Prompt recognition and management of these reactions are essential.

Octagam is contraindicated in patients with a known severe IgA deficiency who have anti‑IgA antibodies, a history of anaphylactic reactions to immunoglobulin products, or uncontrolled hypercoagulable states. Clinicians should evaluate each patient’s medical history before initiating therapy.